David M. Spencer is CSO at BELLICUM PHARMACEUTICALS, INC (BLCM). They have made 10 open-market trades across 1 company since 2015, most recently 2019-01-03.
CIK 0001358403
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BLCM | 92,439 | $87K |
Shares reported on the most recent Form 4, priced at the 2019-01-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BLCM | SELL | 2018-09-04 | 2018-09-05 | $7.04 | $70K | -10.8% | -11.1% | -34.5% |
| BLCM | SELL | 2018-07-18 | 2018-07-20 | $7.63 | $305K | -15.2% | -9.6% | -27.2% |
| BLCM | SELL | 2017-07-10 | 2017-07-12 | $11.54 | $231K | +1.4% | -32.8% | -3.9% |
| BLCM | SELL | 2016-12-05 | 2016-12-05 | $20.00 | $100K | -13.7% | -19.6% | -33.3% |
| BLCM | SELL | 2016-12-01 | 2016-12-05 | $17.39 | $139K | -13.7% | -19.6% | -33.3% |
| BLCM | SELL | 2016-09-23 | 2016-09-23 | $20.19 | $125K | +1.3% | -17.3% | -33.5% |
| BLCM | SELL | 2016-09-22 | 2016-09-23 | $19.68 | $197K | +1.3% | -17.3% | -33.5% |
| BLCM | SELL | 2016-09-21 | 2016-09-23 | $19.96 | $453K | +1.3% | -17.3% | -33.5% |
| BLCM | SELL · 10b5-1 | 2016-09-16 | 2016-09-20 | $20.01 | $50K | +0.5% | -16.6% | -25.6% |
| BLCM | SELL | 2016-08-15 | 2016-08-17 | $20.00 | $20K | -8.2% | +5.2% | +18.2% |
| BLCM | SELL | 2016-07-27 | 2016-07-29 | $15.00 | $150K | +21.0% | +9.1% | +5.9% |
| BLCM | SELL · 10b5-1 | 2015-12-01 | 2015-12-03 | $22.95 | $115K | -35.2% | -2.7% | -46.5% |
| BLCM | SELL · 10b5-1 | 2015-09-11 | 2015-09-15 | $19.00 | $95K | -35.2% | -2.7% | -2.7% |
| BLCM | SELL · 10b5-1 | 2015-06-16 | 2015-06-19 | $22.96 | $459K | -35.2% | -2.7% | -2.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.